Forward Looking Information

Size: px
Start display at page:

Download "Forward Looking Information"

Transcription

1 Vital Signs, Inc.

2 Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned that such statements are only predictions and that actual events or results may differ materially. These forward-looking statements speak only as of this date. We undertake no obligation to publicly release the results of any revisions to the forward-looking statements made today to reflect events or circumstances after today, or to reflect the occurrence of unanticipated events.

3 Key Investment Highlights One of the Most Recognized Names of Single Use Airway Management Products among Anesthesiologists Continuous Leadership in Anesthesia and Respiratory Business Four Significant New Products Three in Anesthesia, one in Respiratory Two of which are converting from Reusable to Single Use Unique Dual Platform in Growing Sleep Disorders Market Growth through additional sleep centers Sale of Breas products through our sleep centers Five New Products Global Expansion Opportunities Source: Frost & Sullivan 2005, IMS, company and analyst reports 3

4 Vital Signs Revenue History Thirty Years of Growth and Success $200 $175 $150 $ Millions $125 $100 CAGR: 19% $75 $50 $25 $0 '73 '74 '75 '76 '77 '78 '79 '80 '81 '82 '83 '84 '85 '86 '87 '88 '89 '90 '91 '92 '93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 4

5 Vital Signs Overview Anesthesia Respiratory/ Critical Care Sleep Pharmaceutical Services Revenue: $93.3mm Revenue: $42.4mm Revenue: $41.5mm Revenue: $16.8mm 48.1% 21.9% 21.4% 8.6% #1 in Anesthesia Circuits and Masks (46% mkt share) 1 #1 in Pressure infusors (51% mkt share) 1 #2 in Resuscitators (22% mkt share) 1 #2 Arterial blood gas kits (19% mkt share) 1 Therapeutics (Breas): Predominantly Europe Planned expansion to U.S. and Asia Diagnostics (SSA) Includes all 12 Fortune Global 50 pharmaceutical companies Expansion of sleep centers 1 Source: IMS (2005) 5

6 Anesthesia & Respiratory Market Market factors Frost & Sullivan forecasts the anesthesia disposables market to grow at a 13.3% CAGR 2004 through Increased use of single-patient use products due to risk of infection Six States now require hospitals to publicly announce their infection rates (32 others considering legislation) 2 Hospital Acquired Infections (HAI) cause more deaths annually than AIDS, breast cancer, and car accidents combined 3 Pennsylvania Health Care Cost Containment Council (PHC4) 2 Additional $2 Billion in hospital charges due to treating infections in 2004 Hospital stays increased from 5.4 days to 20 days when HAI occurs (Cost of $128,000 per patient) Cost effectiveness associated with single-use products 1 U.S. market only; source: Frost & Sullivan, Medtech Insight, Healthcare Trends: Infection Control Efforts Intensify, September Committee to Reduce Infection Deaths (RID), 6

7 Strengths in Anesthesia & Respiratory Significant recurring revenue Business Strengths Rest of the world 10% Europe 8% U.S. 82% Large recurring revenue stream from single-use airway management products Market leading products with strong brand recognition Longstanding relationships with hospitals, distributors and GPOs Strong R&D pipeline and state-of the-art manufacturing Single-use products contribute over 99% of revenue 7

8 New Product Releases in Anesthesia U.S releases Vital-Seal Laryngeal Mask Airway (patented feature) January Vital-View II Laryngoscope System (patent pending) January Breathing Bag/Circuit Lower Cost Latex Free (patented) June Vital Signs has a long history of first-to-market product innovation 8

9 New Product Releases in Respiratory U.S releases Broselow Pediatric Error Prevention System (patented) January C-CO 2 Indicator (patented) January Limb-Θ Ventilator Circuit (patented) April Vital Signs has a long history of first-to-market product innovation 9

10 Sleep Market Market fundamentals 1 Market factors 2 $ Billionss CAGR: 15.4% Large untapped OSA market million suffer from symptomatic or severe OSA in the U.S. 2.9 million sufferers are currently being treated Co-morbidities/awareness Increasing awareness by physicians and patients Co-morbidities include: diabetes, stroke, hypertension, congestive heart failure, depression and other 3 1 Includes U.S. sleep diagnostic and treatment devices as well as sleep service provider markets 2 Frost & Sullivan 2005, Medtech Insight, IMS, company and analyst reports 3 American Academy of Sleep Medicine, 2005, Cost Effectiveness of Sleep Medicine 10

11 Breas Overview Business Overview Sales by geography ¾ Breas Manufactures sleep therapy Rest of the world 10% equipment (isleep line), and ventilators for homecare (Vivo line) ¾ Afforded VSI entrée into fastgrowing sleep market ¾ Breas, based in Sweden, is a wellrecognized brand in Europe Plans to introduce 4 Europe 90% products in Europe in Q1/Q

12 New Product Releases in Sleep Europe 2005 Q4 limited releases Vivo 30 Bi-level ventilator Vivo 40 Bi-level ventilator HAOI Humidifier imask Ultra-soft Cushion Nasal mask Europe 2006 releases isleep 10 Conventional CPAP isleep 20 Provides built-in humidifier isleep 20i Intelligent CPAP with built-in humidifier isleep 22 Bi-level CPAP with humidifier Q2 Release Q3 Release With the introduction of these products, Vital signs will significantly broaden its product line within the high growth OSA market 12

13 Sleep Services of America Overview SSA operates 52 sleep diagnostic centers 1 in the Mid-Atlantic region Improving business fundamentals Record profitability: 49.5% increase in EBIT FY 05 over FY 04 Same store growth 2 : 22.3% increase FY 05 over FY 04 Closed marginally profitable sleep labs during FY 04 Prestigious Sleep Lab affiliations Johns Hopkins University of Maryland Duke University Owned by Vital Signs (70%) and Johns Hopkins Medicine (30%) 1 As of September 30, Calculated based on currently operated sleep labs 13

14 Pharmaceutical Services Market factors Trend toward outsourcing of compliance functions FDA 15%+ increase in IT spending by Life Sciences industry, in part due to Part 11 compliance FDA Regulatory Climate Efforts to systemize and control costs of compliance by companies Increased capital spending in pharmaceutical, medical devices and biotechnology sectors Vital Signs position Full spectrum of FDA compliance related validation and implementation consulting services Development of proprietary software products for FDA regulated customers Clients includes all 12 Fortune Global 50 pharmaceutical companies Source: Frost & Sullivan 2005, IMS, company and analyst reports 14

15 Recent Acquisitions Acquisition of Baxter Airway Acquired next largest competitor in the segment Low acquisition multiple - 1.0x times of sales Consolidation of manufacturing into VITL s Totowa plant created greater efficiency Acquisition of Futall AB Provides Vital Signs access to a key, patented CO 2 detection technology Acquired product provides early detection of accidental intubation of the esophagus Complements existing airway product lines 15

16 Financial Overview

17 Q versus Q (In Thousands except EPS figures) Q Q Net Change Net Revenues 47,730 45, % Gross Profit 24,203 22, % Gross Margin 50.7% 49.7% 2.0% Income from Continuing Operations 6,661 5, % Net Income 6,660 5, % Basic Net Earnings % Diluted Net Earnings % 17

18 Net Revenue by Segment Net Revenues (In Thousands $) Q Q Net Change Anesthesia 22,348 20, % Respiratory/Critical Care 10,560 10, % Sleep Disorders/Personal Ventilation 10,176 10,752 (5.4)% Pharmaceutical 4,646 4,671 (0.5)% Technologies 18

19 Gross Profit by Segment Gross Profit By Segment Q Q Anesthesia 51.0% 51.0% Respiratory/Critical Care 55.3% 56.6% Sleep Disorders/Personal Ventilation 52.7% 43.8% Pharmaceutical Technologies 34.3% 42.8% 19

20 Balance Sheet (In Thousands $) (Unaudited) December 31, Cash and cash equivalents 86,033 79,883 Accounts Receivable 31,327 31,548 Inventory 18,977 17,750 Current Assets Total Assets Current Liabilities 140, ,568 17, , ,015 17,346 Total Liabilities Shareholders' equity 17, ,406 17, ,213 20

21 EPS Growth $2.50 CAGR: 17.5% $2.06 $2.40 $2.00 $1.72 $1.50 $1.48 $1.00 $0.50 $ E Notes: Represents mid-point of management s guidance range for diluted EPS for FY

22 Margin Improvements 60% 50% 49.7% 50.3% 50.8% Gross Margin 40% 30% 20% 10% 0% Operating Margin 17.80% 18.70% 20.80% Revenue ($mm)

23 Balance Sheet Strengths $81.8 million in cash at 9/30/05 ($6.38 / share) No debt Dividends of $0.27/share during FY 2005, representing a 19.2% CAGR since FY 2003 Cash provided by operating activities of $30.8mm during fiscal

24 Guidance Fully diluted EPS from continuing operations for FY 2006 between $2.35 and $2.45 per share 1 Continued high single-digit growth in Anesthesia and Respiratory/Critical Care segments Return to profitability at Breas Revenue growth between 15-20% at Sleep Service of America 1 Without giving effect to compensation expense for options granted to employees under FASB 123(R) 24

25 Key Investment Highlights One of the Most Recognized Names of Single Use Airway Management Products among Anesthesiologists Continuous Leadership in Anesthesia and Respiratory Business Four Significant New Products Three in Anesthesia, one in Respiratory Two of which are converting from Reusable to Single Use Unique Dual Platform in Growing Sleep Disorders Market Growth through additional sleep centers Sale of Breas products through our sleep centers Five New Products Global Expansion Opportunities Source: Frost & Sullivan 2005, IMS, company and analyst reports 25

Vital Signs at a Glance

Vital Signs at a Glance 1 Vital Signs at a Glance Vital Signs is a leading designer, manufacturer, and marketer of airway management products for the anesthesia, respiratory/critical care, interventional cardiology/radiology,

More information

Financial Presentation

Financial Presentation Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with

More information

Full Year Update FY2011 May 2011

Full Year Update FY2011 May 2011 Full Year Update FY2011 May 2011 1 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated US$3.0+ billion and growing market opportunity High level

More information

FY07 Full Year Update & Overview

FY07 Full Year Update & Overview FY07 Full Year Update & Overview Investment Highlights Leading player in respiratory humidification systems Consistent growth strategy Estimated US$2+ billion and growing market opportunity High level

More information

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking

More information

Investment Highlights

Investment Highlights FY08 Full Year Update and Overview Investment Highlights Leading player in respiratory humidification systems Consistent growth strategy Estimated US$2.5+ billion and growing market opportunity High level

More information

For personal use only

For personal use only FY2015 Half Year Results Presentation 6 months ended 30 September 2014 24 28 November 2014 1 First half result highlights H1 FY15 (6 months to 30 September 2014) PCP CC 1 Operating profit +8% +64% RAC

More information

FY06 Full Year Update & Overview

FY06 Full Year Update & Overview FY06 Full Year Update & Overview Investment Highlights Leading player in heated humidification systems Consistent growth strategy Estimated US$2+ billion and growing market opportunity High level of innovation

More information

2014 Full Year Results Presentation. Year ended 31 March 2014

2014 Full Year Results Presentation. Year ended 31 March 2014 2014 Full Year Results Presentation Year ended 31 March 2014 26-30 May 2014 1 Full year result highlights 12 months to 31 March 2014 NZ$M PCP CC 1 Record net profit after tax 97.1 +26% +46% Record operating

More information

Half Year Update FY2012 November 2011

Half Year Update FY2012 November 2011 Half Year Update FY2012 November 2011 1 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated US$3.0+ billion and growing market opportunity High

More information

For personal use only

For personal use only Fisher & Paykel Healthcare Inspired and world-leading healthcare solutions FY2016 HALF YEAR RESULTS PRESENTATION 6 months ended 30 September 2015 1 First Half Result Highlights H1 FY2016 (6 months to 30

More information

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009 FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)

More information

ASX Investor Presentation

ASX Investor Presentation ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited

More information

For personal use only

For personal use only Fisher & Paykel Healthcare Inspired and world-leading healthcare solutions DEUTSCHE BANK CRAIGS NZ COMPANIES DAY Sydney, 8 March 2016 1 Investment Highlights o A leader in respiratory and OSA treatment

More information

Fisher & Paykel Healthcare

Fisher & Paykel Healthcare Fisher & Paykel Healthcare Deutsche Bank / Craigs New Zealand Corporate Day 1 Sydney March 2014 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

Goldman Sachs JBWere Australasian Investment Forum New York - 7 March 2006

Goldman Sachs JBWere Australasian Investment Forum New York - 7 March 2006 Goldman Sachs JBWere Australasian Investment Forum New York - 7 March 2006 Investment Highlights Leading player in heated humidification systems Consistent growth strategy Estimated US$2+ billion and growing

More information

Investor Presentation. Q April 26, 2018

Investor Presentation. Q April 26, 2018 Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

Investor Presentation. Q October 26, 2017

Investor Presentation. Q October 26, 2017 Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

BALCHEM CORPORATION. Q Investor Relations Presentation

BALCHEM CORPORATION. Q Investor Relations Presentation BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life

More information

Forward-Looking Statements

Forward-Looking Statements Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.

More information

Investor Presentation. Q May 21, 2018

Investor Presentation. Q May 21, 2018 Investor Presentation Q3 2018 May 21, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

Company Profile 2011

Company Profile 2011 Company Profile 2011 Disclaimer This presentation contains forward-looking statements based on the currently held beliefs and assumptions of our management, which are expressed in good faith and in their

More information

Summary of Results for the First Half of FY2015/3

Summary of Results for the First Half of FY2015/3 Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial

More information

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

Consolidated: Financial Summary

Consolidated: Financial Summary FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018 CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm

More information

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

Investor Presentation June 2012 NASDAQ: CEMI

Investor Presentation June 2012 NASDAQ: CEMI Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act

More information

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Telekom Austria Group Results for the 1st Quarter May 27, 2003 Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

Global Leaders in Sleep and Respiratory Medicine. Investor Update Q Peter Farrell, PhD. Chairman & CEO. Q2 Fiscal Year 2007 ResMed

Global Leaders in Sleep and Respiratory Medicine. Investor Update Q Peter Farrell, PhD. Chairman & CEO. Q2 Fiscal Year 2007 ResMed Global Leaders in Sleep and Respiratory Medicine Investor Update Q2 2007 Peter Farrell, PhD Chairman & CEO Q2 Fiscal Year 2007 ResMed 2006 1 Forward-Looking Statements Statements contained in this presentation

More information

ELICA 2012 Q3 RESULTS. November 14,

ELICA 2012 Q3 RESULTS. November 14, ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains

More information

Medifocus, Inc. OTCQX: MDFZF TSXV: MFS

Medifocus, Inc. OTCQX: MDFZF TSXV: MFS Medifocus, Inc. OTCQX: MDFZF TSXV: MFS www.medifocusinc.com Develops and commercializes minimally invasive focused heat thermotherapy systems for the treatment of cancer and other diseases January 2014

More information

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating

More information

Q Investor Kit JANUARY-MARCH 2013

Q Investor Kit JANUARY-MARCH 2013 Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Itamar Medical. December Investors Presentation.

Itamar Medical. December Investors Presentation. Itamar Medical December 2017. Investors Presentation. Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration

More information

REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS

REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS IRVING, Texas August 8, 2018 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage

More information

OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss

OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information

More information

A GLOBAL LEADER IN PERSONALIZED NUTRITION

A GLOBAL LEADER IN PERSONALIZED NUTRITION A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking

More information

Interim report Second quarter 2017 and subsequent events (Unaudited)

Interim report Second quarter 2017 and subsequent events (Unaudited) SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities

More information

Leading Intimate Healthcare. Investor presentation Q1 2007/08

Leading Intimate Healthcare. Investor presentation Q1 2007/08 Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1

More information

Global Invisible Braces Market: Trends, Opportunities and Forecasts ( )

Global Invisible Braces Market: Trends, Opportunities and Forecasts ( ) Global Invisible Braces Market: Trends, Opportunities and Forecasts (2016-2021) By Types Clear Aligners, Ceramic, Lingual By Region Americas, Europe, Middle East, Africa, Asia-Pacific By Country- USA,

More information

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations

More information

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION

More information

Enel Américas 1Q 2018 results

Enel Américas 1Q 2018 results Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation

More information

Coloplast A/S. Investor presentation 1H 2005/06

Coloplast A/S. Investor presentation 1H 2005/06 Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

Natus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017

Natus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Natus Medical Incorporated Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Forward-Looking Statements This presentation contains forward-looking statements including statements regarding our

More information

J.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009

J.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009 J.P. Morgan 27 th Annual Healthcare Conference 1 San Francisco January 14 th, 2009 Introduction This slide presentation contains forward-looking statements which are subject to change based on various

More information

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers

More information

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish

More information

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,

More information

DELICA D:5 ACTIVE GEAR 0

DELICA D:5 ACTIVE GEAR 0 DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion

More information

Fiscal 2019 Annual Meeting of Shareholders December 18, Presentation by Lori Woods, Chief Executive Officer

Fiscal 2019 Annual Meeting of Shareholders December 18, Presentation by Lori Woods, Chief Executive Officer Fiscal 2019 Annual Meeting of Shareholders December 18, 2018 Presentation by Lori Woods, Chief Executive Officer Safe Harbor Statement Statements in this presentation about IsoRay's future expectations,

More information

27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009

27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009 27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»

More information

Molecular Diagnostic Solutions for Urologic Cancer

Molecular Diagnostic Solutions for Urologic Cancer 1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This

More information

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo

More information

Bank of America 38 th Annual Investment Conference. San Francisco, CA September 17 th, 2008

Bank of America 38 th Annual Investment Conference. San Francisco, CA September 17 th, 2008 Bank of America 38 th Annual Investment Conference 1 San Francisco, CA September 17 th, 2008 Introduction This slide presentation contains forward-looking statements which are subject to change based on

More information

Coloplast A/S. Investor Presentation 2005/06

Coloplast A/S. Investor Presentation 2005/06 Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &

More information

Myriad Genetics Corporate Presentation 06/13/2018

Myriad Genetics Corporate Presentation 06/13/2018 Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

THIRD QUARTER REPORT 2011 (UNAUDITED)

THIRD QUARTER REPORT 2011 (UNAUDITED) THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor

More information

TELECONFERENCE Q August 2015

TELECONFERENCE Q August 2015 TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

FY2007 Consolidated Financial Overview

FY2007 Consolidated Financial Overview FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking

More information

January 2017 Investor Presentation. confidently live life with ease

January 2017 Investor Presentation. confidently live life with ease January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

DARA Reports Year-End 2012 Financial Results

DARA Reports Year-End 2012 Financial Results April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,

More information

Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results

Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

1Q2017 法人說明會 Jun. 9, 2017

1Q2017 法人說明會 Jun. 9, 2017 1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product

More information

FIRSTQUARTER2018 RESULTSPRESENTATION

FIRSTQUARTER2018 RESULTSPRESENTATION FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection

More information

1Q 2015 Results A Positive Start to 2015

1Q 2015 Results A Positive Start to 2015 1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results

More information

Third-quarter results 2013

Third-quarter results 2013 Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

Investor Presentation. Q October 25, 2018

Investor Presentation. Q October 25, 2018 Investor Presentation Q1 2019 October 25, 2018 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results

More information

Global Prefilled Syringes Market: Trends, Opportunities and Forecasts ( )

Global Prefilled Syringes Market: Trends, Opportunities and Forecasts ( ) Global Prefilled Syringes Market: Trends, Opportunities and Forecasts (2016-2021) By Material - Glass and Plastic By Filling Capabilities Single Chamber and Dual/Multiple Chamber By Major Applications

More information

Investor Presentation

Investor Presentation Investor Presentation January 2012 Forward Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933,

More information

ANESTHESIA AND RESPIRATORY DEVICES: GLOBAL MARKETS. HLC167A February Vijay Laxmi Project Analyst ISBN:

ANESTHESIA AND RESPIRATORY DEVICES: GLOBAL MARKETS. HLC167A February Vijay Laxmi Project Analyst ISBN: ANESTHESIA AND RESPIRATORY DEVICES: GLOBAL MARKETS HLC167A February 2014 Vijay Laxmi Project Analyst ISBN: 1-56965-704-1 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301

More information

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List

More information

Monogram Announces 2008 Second Quarter Financial Results

Monogram Announces 2008 Second Quarter Financial Results Monogram Announces 2008 Second Quarter Financial Results 66% Revenue Growth; HERmark Breast Cancer Assay launched commercially - Conference call today at 4:30 p.m. ET - SOUTH SAN FRANCISCO, Calif., July

More information

Cepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012

Cepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012 Cepheid The MDx Growth Leader William Blair Growth Stock Conference June 12, 2012 Forward Looking Statement During the course of this presentation, we may make projections or other forward looking statements

More information

Corporate Presentation

Corporate Presentation Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking

More information

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total

More information

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER

More information